Detalhe da pesquisa
1.
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Ann Hematol
; 100(2): 429-436, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33161453
2.
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.
Eur J Cancer
; 60: 154-65, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27127905
3.
Activity and toxicity profiles of the combinations bendamustine-lenalidomide-dexamethasone and bendamustine-bortezomib-dexamethasone for advanced stage multiple myeloma.
Leuk Lymphoma
; 55(5): 1191-3, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23829305
4.
Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.
Leuk Lymphoma
; 51(5): 937-40, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20350279